Linker Information
General Information of This Linker
| Linker ID |
LIN0TCMUB
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Noncleavable linker
|
|||||
| Antibody-Linker Relation |
Uncleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
NJH-395 [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
0.00%
|
|||
| Patients Enrolled |
Patients with nonbreast HER2+ advanced malignancies.
|
||||
| Administration Dosage |
5 dose cohorts (0.10-1.60 mg/kg).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03696771 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1, multicenter, open-label dose finding study of NJH395, administered intravenously in patients with non-breast HER2+ advanced malignancies.
|
||||
References